- Home
- CRF vs ORIC Comparison
CRF vs ORIC Comparison
Compare CRF & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRF | ORIC |
|---|---|---|
| Founded | 1973 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CRF | ORIC |
|---|---|---|
| Price | $8.02 | $10.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 1.1M | ★ 1.3M |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 18.10% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | ★ $11,461,786.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.38 | ★ N/A |
| Revenue Growth | ★ 6.53 | N/A |
| 52 Week Low | $5.70 | $3.90 |
| 52 Week High | $9.56 | $14.93 |
Technical Indicators
Market Signals| Indicator | CRF | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 56.58 | 31.43 |
| Support Level | $7.58 | $10.45 |
| Resistance Level | $8.05 | $12.50 |
| Average True Range (ATR) | 0.09 | 0.81 |
| MACD | 0.02 | -0.15 |
| Stochastic Oscillator | 93.62 | 5.36 |
Price Performance
Historical ComparisonAbout CRF Cornerstone Total Return Fund Inc. (The)
Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology; Health Care; Financials; Communication Services; Consumer Discretionary; Industrials; Exchange-Traded Funds; Utilities; Energy; Real Estate and others.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.